Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded RNA molecules, 20-25 nucleotides in length, that play a variety of roles in biology. Most notably, siRNA is involved in the RNA interference (RNAi) pathway, where it interferes with the expression of a specific gene. In addition to their role in the RNAi pathway, siRNAs also act in RNAi-related pathways, e.g., as an antiviral mechanism or in shaping the chromatin structure of a genome; the complexity of these pathways is only now being elucidated.
A protein that stimulates blood vessel growth worsens ovarian cancer, but its production can be stifled by a tiny bit of RNA wrapped in a fatty nanoparticle, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the Journal of the National Cancer Institute.
Researchers at the University of Maryland at College Park have discovered that Normal Human Bronchial Epithelial (NHBE) cells cultured in medium with elevated zinc level, at the high end of plasma zinc attainable by oral supplementation, demonstrated inhibition of cell growth, up-regulation of growth arrest and DNA damage-induced gene (Gadd45) mRNA and protein expression, and blockage of G2/M cell cycle progression.
RNA interference (RNAi) represents an innovative new strategy for using small RNA molecules to silence specific genes associated with disease processes, and a series of review articles describing the state-of-the-art and potential therapeutic applications of RNAi and microRNAs will begin with two review papers in the January 2008 issue (Volume 19, Number 1) of Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc.
In some ways, HIV resembles a minimalist painter, using a few basic components to achieve dramatic effects.
Researchers from MIT, Alnylam Pharmaceuticals and other institutions have demonstrated the safety of a promising type of genetic therapy that could lead to treatments for a wide range of diseases such as cancer.
It all started with flowers: in the nineties of the last century Norwegian researchers discovered that additional copies of a particular gene in petunias inhibited its activity instead of reinforcing it as had been assumed.
Take a quantum dot, add a coating of poly(ethylene glycol) (PEG), and attach a homing peptide and a piece of small interfering RNA (siRNA), and the result is a targeted nanoparticle that can stop the production of a specific protein by a targeted cell.
A major obstacle in the treatment of infections and other diseases of the brain is the blood-brain barrier, which prevents systemically delivered therapeutic drugs from reaching the brain.
Investigators at St. Jude Children's Research Hospital have used the lowly yeast to gain insights into how a dividing human cell ensures that an identical set of chromosomes gets passed on to each new daughter cell.
Using magnetic nanoparticles labeled with dye molecules, a team of investigators at the Massachusetts General Hospital has developed a delivery vehicle capable of transporting antitumor small interfering RNA (siRNA) molecules into cells.
Researchers in the laboratory of Mark E. Davis at the California Institute of Technology have been using small interfering RNA (siRNA), sometimes known as silencing RNA, to "silence" specific genes that are implicated in certain malignancies.
An effective way to fight leukemia might be to knock out a specific protein that protects cancer cells from dying, a new study shows.
Expression Genetics, Inc., has announced the completion of a Phase I clinical study evaluating the Company's lead drug candidate, EGEN-001.
Using a technology that can quickly screen all 20,000-plus human genes for biological activity, scientists have isolated 87 genes that seem to affect how sensitive human cancer cells are to certain chemotherapy drugs.
In the April 1 issue of G&D, a Korean research team led by Dr. Kyong-Tai Kim (Pohang University) describes how melatonin production is coordinated with the body's natural sleep/wake cycles.
Short pieces of RNA, known as small interfering RNA (siRNA), have the potential to become a new class of anticancer drugs if researchers can solve the problem of how to deliver these fragile molecules to cancer cells.
A promising approach to gene therapy involves short DNA fragments (interfering RNA) that bind to specific genes and block their "translation" into the corresponding, disease-related protein.
Cancer researchers hold great hope that nucleic acid-based therapeutics, such as anticancer genes, antisense oligonucleotides, and small interfering RNA (siRNA) molecules, will prove to be powerful antitumor agents.
Researchers at Johns Hopkins have discovered that a tiny piece of genetic code apparently goes where no bit of it has gone before, and it gets there under its own internal code.
Efforts to treat cancer using genes and other oligonucleotides, such as short interfering RNA (siRNA), that turn off the biochemical processes that trigger malignancies have been hindered by difficulties in delivering nucleic acids to tumors.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.